Update on the optimal use of bortezomib in the treatment of multiple myeloma

References

• BarlogieBMitchellAvan RheeFEpsteinJMorganGJCrowleyJCuring myeloma at last: defining criteria and providing the evidenceBlood2014124203043305125293776
   PubMed Web of Science ®Google Scholar
• RajkumarSVRichardsonPGHideshimaTProteasome inhibition as a novel therapy target in human cancerJ Clin Oncol2005233639639 Review
   Web of Science ®Google Scholar
• AronsonLIDaviesFEDangER: protein ovERload. Targeting protein degradation to treat myelomaHaematologica20129781119113022580998
   PubMed Web of Science ®Google Scholar
• QiangYWHuBChenYProteasome inhibitors and bone diseaseSemin Hematol201249324324822726547
   PubMed Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJA phase 2 study of bortezomib in relapsed, refractory myelomaN Engl J Med2003348262609261712826635
   PubMed Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJExtended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trialCancer200610661316131916470606
   PubMed Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJClinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myelomaBlood200510692977298116020506
   PubMed Web of Science ®Google Scholar
• JagannathSBarlogieBBerensonJRUpdated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myelomaBr J Haematol2008143453754018783399
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med2005352242487249815958804
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWReversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelineBr J Haematol2009144689590319170677
   PubMed Web of Science ®Google Scholar
• OrlowskiRZNaglerASonneveldPRandomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progressionJ Clin Oncol200725253892390117679727
   PubMed Web of Science ®Google Scholar
• GarderetLIacobelliSMoreauPSuperiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the chronic leukemia working party of the European Group for Blood and Marrow TransplantationJ Clin Oncol201230202475248222585692
   PubMed Web of Science ®Google Scholar
• RichardsonPGXieWJagannathSA phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaBlood2014123101461146924429336
   PubMed Web of Science ®Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: sub-analysis of patients with renal impairment in the phase III MMY-3021 studyHaematologica20151005e207e21025596270
   PubMed Web of Science ®Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyLancet Oncol201112543144021507715
   PubMed Web of Science ®Google Scholar
• RichardsonPGXieWMitsiadesCSingle-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathyJ Clin Oncol200927213518352519528374
   PubMed Web of Science ®Google Scholar
• BarlogieBAnaissieEvan RheeFIncorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3Br J Haematol2007138217618517593024
   PubMed Web of Science ®Google Scholar
• HarousseauJLAttalMAvet-LoiseauHBortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trialJ Clin Oncol201028304621462920823406
   PubMed Web of Science ®Google Scholar
• SonneveldPSchmidt-WolfIGvan der HoltBBortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trialJ Clin Oncol201230242946295522802322
   PubMed Web of Science ®Google Scholar
• CavoMTacchettiPPatriarcaFBortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 studyLancet201037697582075208521146205
   PubMed Web of Science ®Google Scholar
• SonneveldPGoldschmidtHRosiñolLBortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trialsJ Clin Oncol201331263279328723897961
   PubMed Web of Science ®Google Scholar
• MoreauPHulinCMacroMVTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trialBlood2016127212569257427002117
   PubMed Web of Science ®Google Scholar
• RichardsonPGWellerELonialELenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaBlood2010116567968620385792
   PubMed Web of Science ®Google Scholar
• San MiguelJFSchlagRKhuagevaNKBortezomib plus melphalan and prednisone for initial treatment of multiple myelomaN Engl J Med2008359990691718753647
   PubMed Web of Science ®Google Scholar
• MateosMVOriolAMartinez-LópezJBortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trialLancet Oncol2010111093494120739218
   PubMed Web of Science ®Google Scholar
• DurieBHoeringARajkumarVBortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777Blood20151262325
   Web of Science ®Google Scholar
• AugustsonBMBegumGDunnJAEarly mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 – Medical Research Council Adult Leukaemia Working PartyJ Clin Oncol200523369219922616275935
   PubMed Web of Science ®Google Scholar
• BladéJFernández-LlamaPBoschFRenal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institutionArch Intern Med199815817188918939759684
   PubMedGoogle Scholar
• Chanan-KhanAAKaufmanJLMehtaJActivity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective studyBlood200710962604260617138816
   PubMed Web of Science ®Google Scholar
• LaroccaAPalumboAHow I treat fragile myeloma patientsBlood20153120152015
   Google Scholar
• NiesvizkyRFlinnIWRifkinRCommunity-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimensJ Clin Oncol201533333921392926056177
   PubMed Web of Science ®Google Scholar
• BergsagelPLMateosMVGutierrezNCRajkumarSVSan MiguelJFImproving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myelomaBlood2013121688489223165477
   PubMed Web of Science ®Google Scholar
• Avet-LoiseauHUltra high-risk myelomaHematology Am Soc Hematol Educ Program2010201048949321239841
   PubMed Web of Science ®Google Scholar
• JagannathSRichardsonPGSonneveldPBortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trialsLeukemia200721115115717096017
   PubMed Web of Science ®Google Scholar
• NairBvan RheeFShaughnessyJDJrSuperior results of total therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBlood2010115214168417320124509
   PubMed Web of Science ®Google Scholar
• WeinholdNHeuckCJRosenthalAClinical value of molecular sub-typing multiple myeloma using gene expression profilingLeukemia201630488388826669972
   PubMed Web of Science ®Google Scholar
• DimopoulosMSiegelDSLonialSVorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyLancet Oncol201314111129114024055414
   PubMed Web of Science ®Google Scholar
• San-MiguelJFHungriaVTYoonSSPanobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialLancet Oncol201415111195120625242045
   PubMed Web of Science ®Google Scholar
• RichardsonPGSchlossmanRLAlsinaMPANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myelomaBlood2013122142331233723950178
   PubMed Web of Science ®Google Scholar
• RichardsonPGBriembergHJagannathSFrequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomibJ Clin Oncol200624193113312016754936
   PubMed Web of Science ®Google Scholar
• LonialSWallerEKRichardsonPGRisk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaBlood2005106123777378416099887
   PubMed Web of Science ®Google Scholar
• NucciMAnaissieEInfections in patients with multiple myeloma in the era of high-dose therapy and novel agentsClin Infect Dis20094981211122519769539
   PubMed Web of Science ®Google Scholar
• Chanan-KhanASonneveldPSchusterMWAnalysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyJ Clin Oncol200826294784479018711175
   PubMed Web of Science ®Google Scholar
• JagannathSVijRStewartAKAn open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myelomaClin Lymphoma Myeloma Leuk201212531031823040437
   PubMed Web of Science ®Google Scholar
• DimoupoulosMAMoreauPPalumboACarfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyLancet Oncol2016171273826671818
   PubMed Web of Science ®Google Scholar
• StewartAKRajkumarSVDimopoulosMACarfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaN Engl J Med2015372214215225482145
   PubMed Web of Science ®Google Scholar
• JakubowiakAJDytfeldDGriffithKAA phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaBlood201212091801180922665938
   PubMed Web of Science ®Google Scholar
• KumarSKLaPLantBRoyVPhase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibBlood Cancer J20154e338
   Web of Science ®Google Scholar
• KumarSKBerdejaJGNiesvizkyRSafety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 studyLancet Oncol201415131503151225456369
   PubMed Web of Science ®Google Scholar
• MoreauPMassziTGrzaskoNOral ixazomib, lenalidomide and dexamethasone for multiple myelomaN Engl J Med2016374171621163427119237
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteCommon Terminology Criteria for Adverse Events v3.0 (CTCAE) Available from: https://ctep.cancer.gov/proto-coldevelopment/electronic_applications/docs/ctcaev3.pdfAccessed January 27, 2017
   Google Scholar